Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (CPH) ends the June quarter with $1.63 million worth of generated revenue, an 18 per cent increase on its March figures
  • The company says its Canadian cannabis business bought in $966,459 worth of revenue, while its Swiss nutraceutical business notched up $607,344
  • CPH ended June cashflow negative and with $13.56 million in the bank, topping up that balance over July to end the month with $16 million
  • It also signed an agreement with Red Light Holland to merge, listed on the US OTCQB market and acquired psychedelic’s business Halucenex Life Sciences
  • Creso shares are trading up 9.09 per cent at 12 cents per share

Creso Pharma (CPH) has ended the June quarter with $1.63 million worth of generated revenue, an 18 per cent increase on its March figures.

The cannabis and psychedelics company’s latest quarterly report shows Mernova Medicinal, CPH’s Canadian business, bought in $966,459 worth of revenue.

Creso’s Swiss nutraceutical business also notched up $607,344 in revenue during the period, helping CPH beat its 2020 June quarter revenue total by 451 per cent.

CPH ended June cashflow negative with a balance of $6.93 million and a total of $13.56 million worth of cash in the bank.

The company has since topped up that balance over July via the exercise of options, helping Creso end the month with around $16 million in the bank.

Activities wise, June was a busy quarter for Creso Pharma, which announced it had signed an agreement to merge with Red Light Holland.

Under the proposed merger, CPH and psychedelics company Red Light Holland would combine to create a new business named The HighBrid Lab.

Additionally, CPH completed its US OTCQB listing during the period, giving it access to more North American investors.

Since the end of June, Creso has also finished its acquisition of Canadian psychedelics company Halucenex Life Sciences.

CPH Non-Executive Chairman Adam Blumenthal said the newly acquired business was focussed on testing psilocybin — the active ingredient in magic mushrooms — on those with PTSD.

“This quarter solidified Creso Pharma’s intent to become a world leader in the psychedelic, CBD, and recreational and medicinal cannabis space,” Mr Blumenthal said.

“The successful acquisition of Halucenex is a major milestone for the Company, as it looks to commercialise new psychedelic-assisted psychotherapy treatments in the future.”

Creso Pharma shares were trading up 9.09 per cent at 12 cents each at 12:02 pm AEST.

CPH by the numbers
More From The Market Herald

" Creso Pharma (ASX:CPH) signs potential partnership with Gotro for Sierra pet products

Creso Pharma (ASX:CPH) signs a heads of agreement with leading pet care distributor, Gotro Global, to…
The Market Herald Video

" Botanix Pharmaceuticals (ASX:BOT) accelerates Sofpironium Bromide NDA filing

Botanix Pharmaceuticals (ASX:BOT) has accelerated the submission of a New Drug Approval (NDA) for its Sofpironium…
The Market Herald Video

" ResApp (ASX:RAP) extends Medgate licence agreement in line with expansion plans

ResApp Health (ASX:RAP) has agreed to a 12 month extension to its commercial licence agreement with…

" Alterity Therapeutics (ASX:ATH) doses first patient in MSA trial

Alterity Therapeutics (ASX:ATH) doses its first patient in a clinical trial for a rare Parkinsonian disorder.